Syndax Pharmaceuticals
SNDX
SNDX
80 hedge funds and large institutions have $150M invested in Syndax Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
2.74% more ownership
Funds ownership: 67.67% → 70.41% (+2.7%)
15% less capital invested
Capital invested by funds: $176M → $150M (-$25.6M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $9K
Holders
80
Holding in Top 10
2
Calls
–
Puts
$9K
Top Buyers
| 1 | +$28.3M | |
| 2 | +$2.73M | |
| 3 | +$1.48M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$763K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$752K |
Top Sellers
| 1 | -$7.03M | |
| 2 | -$5.82M | |
| 3 | -$3.69M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.46M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.63M |